Generate Biomedicines CFO reports buys, option grants

Generate Biomedicines, Inc. executive Jason Silvers, President & CFO, reported several equity transactions.

Rhea-AI Filing Summary

Generate Biomedicines, Inc. executive Jason Silvers, President & CFO, reported several equity transactions. On March 2, 2026, accounts for his daughter and son bought a total of 2,000 shares of common stock in open-market purchases at $16.00 per share, reported as indirect ownership.

On February 26, 2026, he also received two grants of stock options. One option covers 295,608 shares, vesting in two equal installments on February 19, 2029 and February 19, 2030. The other covers 274,493 shares, vesting in forty-eight equal monthly installments following February 19, 2026, in each case contingent on continued service.

Insider Trade Summary

Net Buyer: 2,000 shares

Net Buy 5 txns

Insider Silvers Jason

Role President & CFO

Bought 2,000 shs ($32K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	500	$16.00	$8K
Purchase	Common Stock	500	$16.00	$8K
Purchase	Common Stock	1,000	$16.00	$16K
Grant/Award	Stock Option (Right to Buy)	295,608	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	274,493	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 570,101 contracts (Direct); Common Stock — 500 shares (Indirect, By daughter); Common Stock — 1,000 shares (Indirect, By son)

Footnotes (2)

1. F1. The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date.
2. F2. The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did GENB executive Jason Silvers report?

Jason Silvers reported indirect open-market purchases of 2,000 GENB common shares at $16.00 per share through accounts for his daughter and son, plus two stock option grants covering 295,608 and 274,493 shares with service-based vesting schedules.

How many Generate Biomedicines (GENB) shares were bought in the open market?

A total of 2,000 GENB common shares were bought in open-market transactions. Two purchases of 500 shares each were made in an account for his daughter and one purchase of 1,000 shares in an account for his son, all at $16.00 per share.

What stock option grants did GENB’s President & CFO receive?

He received two stock option grants on February 26, 2026: one for 295,608 shares and another for 274,493 shares. Both are held directly and vest over time, subject to his continued service with Generate Biomedicines.

What are the vesting terms for Jason Silvers’ 295,608-share GENB option?

The 295,608-share stock option vests in two equal installments. Half vests on February 19, 2029, and the remaining half vests on February 19, 2030, provided Jason Silvers continues in service through each respective vesting date.

How does the 274,493-share GENB stock option vest over time?

The 274,493-share stock option vests in 48 equal monthly installments following February 19, 2026. Each monthly vesting is conditioned on Jason Silvers’ continued service with Generate Biomedicines on the applicable vesting date.

Are the GENB common shares purchased held directly by Jason Silvers?

No, the 2,000 GENB common shares are reported as indirectly owned. The filing identifies the nature of ownership as shares held in accounts for his daughter and son rather than directly in his own name.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 05:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Silvers Jason

(Last) (First) (Middle)

GENERATE BIOMEDICINES, INC.

101 SOUTH STREET, SUITE 900

(Street)

SOMERVILLE MA 02143

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Generate Biomedicines, Inc. [ GENB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/02/2026		P		500	A	$16	500	I	By daughter
Common Stock	03/02/2026		P		500	A	$16	500	I	By daughter
Common Stock	03/02/2026		P		1,000	A	$16	1,000	I	By son

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	02/26/2026		A		295,608		(1)	02/25/2036	Common Stock	295,608	$0	295,608	D
Stock Option (Right to Buy)	$16	02/26/2026		A		274,493		(2)	02/25/2036	Common Stock	274,493	$0	274,493	D

Explanation of Responses:

1. The shares underlying this option shall vest in two equal installments on each of February 19, 2029 and February 19, 2030, subject to the Reporting Person's continued service on each such vesting date.

2. The shares underlying this option shall vest in forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Michael Wolf, Attorney-in-Fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.